- Charles River Laboratories ( NYSE: CRL ) has acquired Chicago, Illinois-based high-throughput screening solutions provider, SAMDI Tech.
- The purchase price was $50M in cash for the remaining 80% ownership stake in SAMDI Tech that Charles River ( CRL ) did not already own, subject to customary post-closing adjustments. Additional financial details were not disclosed as the transaction is not expected to have a material impact on Charles River's ( CRL ) financial results in 2023.
- SAMDI Tech will become part of the company’s Discovery and Safety Assessment segment. The business offers a proprietary mass spectrometry technology for high-throughput analysis of biochemical activities and affinity selection MS for identifying binding interactions.
- The acquisition will provide Charles River’s ( CRL ) clients with seamless access to the label-free HTS MS platform and create a comprehensive library of drug discovery solutions.
For further details see:
Charles River acquires SAMDI Tech for $50M in cash